Table 1. Patient characteristics.

No.	Cohort	Age (years)	Gender	Disease	ECOG/PS	Prior treatment	Combined treatment (chemotherapy)
1	Cohort 1	52	M	colonic cancer	0	1st line, mFOLFOX62nd line, S-1	S-1
2	Cohort 1	62	M	pancreatic cancer	1	1st line, GEM2nd line, S-1	S-1
3	Cohort 1	60	M	gastric cancer	0	1st line, S-1	S-1
4	Cohort 2	72	F	rectal cancer	0	1st line, mFOLFOX62nd line, Capectabine	S-1
5	Cohort 2	61	F	bile duct cancer	1	1st line, GEM2nd line, S-1	S-1
6	Cohort 2	75	M	lung cancer	1	1st line, GEM/CDDP2nd line, DTX	none
7	Cohort 3	48	M	hepatocellular carcinoma	1	1st line, 5-FU/CDDP	none
8	Cohort 3	43	M	bile duct cancer	1	1st line, GEM2nd line, GEM/S-1	S-1
9	Cohort 3	53	M	rectal cancer	1	1st line, mFOLFOX6+bevacizumab2nd line, FOLFIRI 3rd line, CPT-11+cetuximab	S-1

ECOG = Eastern Cooperative Oncology Group.

PS = performance status.